https://www.selleckchem.com/products/ki20227.html
on towards clinical application. Oral pre-exposure of mice to two β-lactoglobulin-derived peptides loaded PLGA NPs induced a dose-related partial prevention of CMA symptoms upon challenge to whole whey protein and silenced whey-specific systemic immune response. These findings encourage further development of the concept of peptide-loaded PLGA NPs for CMA prevention towards clinical application.In this study, poly(N-acryloyl-nipecotamide) (PNANAm), poly(N-acryloyl-isonipecotamide) (PNAiNAm), and poly(N-acryloyl-N,N-diethylnipecotamide)
Like
Comment
Share
